Prognostic relevance of SAMSN1 expression in gastric cancer

Kanda,Mitsuro; Shimizu,Dai; Sueoka,Satoshi; Nomoto,Shuji; Oya,Hisaharu; Takami,Hideki; Ezaka,Kazuhiro; Hashimoto,Ryoji; Tanaka,Yuri; Kobayashi,Daisuke; Tanaka,Chie; Yamada,Suguru; Fujii,Tsutomu; Nakayama,Goro; Sugimoto,Hiroyuki; Koike,Masahiko; Fujiwara,Michitaka; Kodera,Yasuhiro

doi:10.3892/ol.2016.5233

Prognostic relevance of SAMSN1 expression in gastric cancer

Authors:
- Mitsuro Kanda
- Dai Shimizu
- Satoshi Sueoka
- Shuji Nomoto
- Hisaharu Oya
- Hideki Takami
- Kazuhiro Ezaka
- Ryoji Hashimoto
- Yuri Tanaka
- Daisuke Kobayashi
- Chie Tanaka
- Suguru Yamada
- Tsutomu Fujii
- Goro Nakayama
- Hiroyuki Sugimoto
- Masahiko Koike
- Michitaka Fujiwara
- Yasuhiro Kodera
View Affiliations

Affiliations: Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Aichi 466‑8550, Japan, Department of Surgery, Aichi‑Gakuin University School of Dentistry, Nagoya, Aichi 464‑8651, Japan
Published online on: October 6, 2016 https://doi.org/10.3892/ol.2016.5233
Pages: 4708-4716

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis for patients with advanced gastric cancer (GC) remains poor. The identification of biomarkers relevant to the recurrence and metastasis of GC is advantageous for stratifying patients and proposing novel molecular targets. In the present study the oncological roles of SAM domain, SH3 domain and nuclear localization signals 1 (SAMSN1), a mediator of B‑cell function, were elucidated in GC. The expression and methylation status of SAMSN1 were investigated in a panel of 11 GC cell lines. Immunohistochemical staining was performed to determine the pattern of SAMSN1 protein expression in gastric tissues. The prognostic impact of SAMSN1 expression was determined by analyzing 175 pairs of surgically resected gastric tissues. A marked decrease in the level of SAMSN1 mRNA was detected in 8/11 GC cell lines as compared with that in a non‑transformed intestinal epithelium cell line (FHs 74) without promoter methylation. The mean expression level of SAMSN1 mRNA was reduced in GC tissues compared with normal adjacent tissues, an observation that was independent of tumor differentiation. The pattern of SAMSN1 protein expression was significantly correlated with that of SAMSN1 mRNA. Low SAMSN1 mRNA expression was significantly associated with tumor size (>60 mm; P=0.026) and shorter overall survival times (P=0.004). Multivariate analysis identified low SAMSN1 mRNA expression as an independent prognostic factor for poor overall survival (hazard ratio, 1.80; 95% confidence interval, 1.07–3.05; P=0.025). The difference in survival between the low and high SAMSN1 expression groups was more marked in patients with stage II/III GC compared to those with stage IV GC. In patients with stage II/III GC who underwent curative surgery, low SAMSN1 expression was associated with reduced disease free survival times. The results of the present study indicate that downregulation of SAMSN1 transcription may affect the progression and recurrence of GC, and therefore may represent a novel biomarker of GC.

View Figures

View References

1	Kanda M, Shimizu D, Fujii T, Sueoka S, Tanaka Y, Ezaka K, Takami H, Tanaka H, Hashimoto R, Iwata N, et al: Function and diagnostic value of Anosmin-1 in gastric cancer progression. Int J Cancer. 138:721–730. 2016. View Article : Google Scholar : PubMed/NCBI
2	Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009. View Article : Google Scholar : PubMed/NCBI
3	Songun I, Putter H, Kranenbarg EM, Sasako M and van de Velde CJ: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 11:439–449. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kanda M, Kobayashi D, Tanaka C, Iwata N, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Nomoto S, et al: Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer. 19:255–263. 2016. View Article : Google Scholar : PubMed/NCBI
5	GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, ; Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, et al: Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA. 303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
6	Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, et al: Asia Pacific Working Group on Gastric Cancer: Screening for gastric cancer in Asia: Current evidence and practice. Lancet Oncol. 9:279–287. 2008. View Article : Google Scholar : PubMed/NCBI
7	Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
8	Kanda M, Oya H, Nomoto S, Takami H, Shimizu D, Hashimoto R, Sueoka S, Kobayashi D, Tanaka C, Yamada S, et al: Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer. Dig Dis Sci. 60:1256–1264. 2015. View Article : Google Scholar : PubMed/NCBI
9	Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H and Kelsen DP: Molecular classification of gastric cancer: A new paradigm. Clin Cancer Res. 17:2693–2701. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kanda M, Shimizu D, Tanaka H, Shibata M, Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, Fujii T, et al: Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget. 7:13667–13679. 2016.PubMed/NCBI
11	Zhu YX, Benn S, Li ZH, Wei E, Masih-Khan E, Trieu Y, Bali M, McGlade CJ, Claudio JO and Stewart AK: The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades. J Exp Med. 200:737–747. 2004. View Article : Google Scholar : PubMed/NCBI
12	Yan Y, Zhang L, Xu T, Zhou J, Qin R, Chen C, Zou Y, Fu D, Hu G, Chen J and Lu Y: SAMSN1 is highly expressed and associated with a poor survival in glioblastoma multiforme. PLoS One. 8:e819052013. View Article : Google Scholar : PubMed/NCBI
13	Claudio JO, Zhu YX, Benn SJ, Shukla AH, McGlade CJ, Falcioni N and Stewart AK: HACS1 encodes a novel SH3-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells. Oncogene. 20:5373–5377. 2001. View Article : Google Scholar : PubMed/NCBI
14	Yamada H, Yanagisawa K, Tokumaru S, Taguchi A, Nimura Y, Osada H, Nagino M and Takahashi T: Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. Genes Chromosomes Cancer. 47:810–818. 2008. View Article : Google Scholar : PubMed/NCBI
15	Noll JE, Hewett DR, Williams SA, Vandyke K, Kok C, To LB and Zannettino AC: SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia. 16:572–585. 2014. View Article : Google Scholar : PubMed/NCBI
16	Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S and Nakao A: Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol. 35:477–483. 2009.PubMed/NCBI
17	Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S and Nakao A: Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog. 50:571–579. 2011. View Article : Google Scholar : PubMed/NCBI
18	Kanda M, Nomoto S, Oya H, Takami H, Shimizu D, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S, et al: The expression of melanoma-associated Antigen D2 both in surgically resected and serum samples serves as clinically rrelevant biomarker of gastric cancer progression. Ann Surg Oncol. 23:(Suppl 2). S214–S221. 2016. View Article : Google Scholar : PubMed/NCBI
19	Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
20	Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011. View Article : Google Scholar : PubMed/NCBI
21	Japanese Gastric Cancer Association, . Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 14:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kanda M, Sugimoto H, Nomoto S, Oya H, Hibino S, Shimizu D, Takami H, Hashimoto R, Okamura Y, Yamada S, et al: B-cell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma. Int J Oncol. 46:641–648. 2015.PubMed/NCBI
23	Sobin LH, Gospodarowicz MK and Wittekind C: International Union Against CancerTNM Classification of Malignant Tumors. 7th. Wiley-Blackwell; New York, NY: pp. 73–77. 2009
24	Kanda M, Sugimoto H, Nomoto S, Oya H, Shimizu D, Takami H, Hashimoto R, Sonohara F, Okamura Y, Yamada S, et al: Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma. Int J Oncol. 45:2005–2012. 2014.PubMed/NCBI
25	Kanda M, Nomoto S, Oya H, Takami H, Hibino S, Hishida M, Suenaga M, Yamada S, Inokawa Y, Nishikawa Y, et al: Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol. 44:44–52. 2014.PubMed/NCBI
26	Oya H, Kanda M, Sugimoto H, Shimizu D, Takami H, Hibino S, Hashimoto R, Okamura Y, Yamada S, Fujii T, et al: Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol. 50:590–600. 2015. View Article : Google Scholar : PubMed/NCBI
27	Shimizu D, Kanda M, Nomoto S, Oya H, Takami H, Hibino S, Suenaga M, Inokawa Y, Hishida M, Takano N, et al: Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. Oncol Rep. 31:1305–1313. 2014.PubMed/NCBI
28	Resende C, Thiel A, Machado JC and Ristimäki A: Gastric cancer: Basic aspects. Helicobacter. 16:(Suppl 1). S38–S44. 2011. View Article : Google Scholar
29	Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y and Oue N: Molecular pathology of gastric cancer: Research and practice. Pathol Res Pract. 207:608–612. 2011. View Article : Google Scholar : PubMed/NCBI
30	Janjigian YY and Kelsen DP: Genomic dysregulation in gastric tumors. J Surg Oncol. 107:237–242. 2013. View Article : Google Scholar : PubMed/NCBI
31	Bird A: Perceptions of epigenetics. Nature. 447:396–398. 2007. View Article : Google Scholar : PubMed/NCBI
32	Jones PA: Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet. 13:484–492. 2012. View Article : Google Scholar : PubMed/NCBI
33	Oya H, Kanda M, Takami H, Hibino S, Shimizu D, Niwa Y, Koike M, Nomoto S, Yamada S, Nishikawa Y, et al: Overexpression of melanoma-associated antigen D4 is an independent prognostic factor in squamous cell carcinoma of the esophagus. Dis Esophagus. 28:188–195. 2015. View Article : Google Scholar : PubMed/NCBI
34	Hibino S, Kanda M, Oya H, Takami H, Shimizu D, Nomoto S, Hishida M, Niwa Y, Koike M, Yamada S, et al: Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus. Oncol Rep. 31:693–700. 2014.PubMed/NCBI
35	Cancer Genome Atlas Research Network, . Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
36	Kanda M, Nomoto S, Oya H, Hashimoto R, Takami H, Shimizu D, Sonohara F, Kobayashi D, Tanaka C, Yamada S, et al: Decreased expression of prenyl diphosphate synthase subunit 2 correlates with reduced survival of patients with gastric cancer. J Exp Clin Cancer Res. 33:882014. View Article : Google Scholar : PubMed/NCBI
37	Wang D, Stewart AK, Zhuang L, Zhu Y, Wang Y, Shi C, Keating A, Slutsky A, Zhang H and Wen XY: Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1. FASEB J. 24:947–956. 2010. View Article : Google Scholar : PubMed/NCBI
38	Lang PA, Recher M, Häussinger D and Lang KS: Genes determining the course of virus persistence in the liver: Lessons from murine infection with lymphocytic choriomeningitis virus. Cell Physiol Biochem. 26:263–272. 2010. View Article : Google Scholar : PubMed/NCBI
39	Stagg J and Galipeau J: Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med. 13:856–867. 2013. View Article : Google Scholar : PubMed/NCBI
40	Ringelhan M, Reisinger F, Yuan D, Weber A and Heikenwalder M: Modeling human liver cancer heterogeneity: Virally induced transgenic models and mouse genetic models of chronic liver inflammation. Curr Protoc Pharmacol. 67:14.31.11–14.31.17. 2014.
41	Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA and Hamilton SM: Gastric adenocarcinoma: Review and considerations for future directions. Ann Surg. 241:27–39. 2005.PubMed/NCBI